The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Top Execs Stress Importance of Emerging Markets, Compliance in New Year's Addresses
January 6, 2012
- Toray to Take Equity Stake in Mitsui’s Subsidiary
January 6, 2012
- Seikagaku Changes Sales Partner for Supartz in US
January 6, 2012
- Astellas Directed to Suspend Export of Gaster to South Korea Due to Use of Unapproved API
January 6, 2012
- Takara Bio, Mie Univ. to Collaborate in Clinical Trial of Cancer Treatment
January 6, 2012
- Meiji Seika Pharma Submits Application for ME2080 to Treat Dravet’s Syndrome
January 6, 2012
- Tivozanib Significantly Improves PFS Compared to Sorafenib in RCC: Astellas
January 6, 2012
- RaQualia Licenses COX-2 Inhibitor in China
January 5, 2012
- Takeda Voluntarily Recalls Bestcall IM Inj. 0.5 g
January 5, 2012
- Arena Submits Response to FDA CRL for Lorcaserin: Eisai
January 5, 2012
- CanBas’ CBP501 Receives Orphan Drug Designation from US FDA
January 5, 2012
- SymBio Initiates PII Trials for Relapsed, Refractory Multiple Myeloma Treatment SyB L-0501
December 28, 2011
- Nippon Kayaku Starts Clinical Study for Remicade Biosimilar
December 28, 2011
- Sanofi-aventis Completes Patient Enrollment for Int’l ATLAS Study for Lantus
December 28, 2011
- 2 ARB/CCB Combination Products Enter Top 100 Sales Ranking in 1st Half of FY2011
December 28, 2011
- Aricept Overtakes Blopress to Take Top Spot in Domestic Drug Sales
December 28, 2011
- Ain Pharmaciez’s Generic Drug Wholesale Subsidiary Showing Steady Growth
December 28, 2011
- Fuji Pharma, Mochida Apply for Japan’s 1st G-CSF Biosimilar
December 27, 2011
- Nippon Kayaku: Pharm Sales Remains Virtually Unchanged in Jun-Nov
December 27, 2011
- Novartis Receives Add’l Approval for Afinitor as 1st pNET Indication in Japan
December 27, 2011
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…